Industry News
Phylogica gets Australian Phylomer patent
Phylogica (ASX:PYC) has won an Australian patent covering its Phylomer peptide libraries as a composition of matter. [ + ]
Phosphagenics’ new opioid patch clears phase I
Phosphagenics’ (ASX:POH) TPM-Oxymorphone patch, its second opioid-based pain patch in development, has met its delivery targets in a phase I trial. [ + ]
Screening human blood for disease markers
Researchers at The Scripps Research Institute in Florida have developed cutting-edge technology that can successfully screen human blood for disease markers. This tool may hold the key to better diagnosing and understanding today’s most pressing and puzzling health conditions, including autoimmune diseases. [ + ]
Plant scientist off to study US corn as Fulbright scholar
A young plant biologist who developed a passion for the environment when he took up surfing in primary school has been awarded a 2013 Fulbright Western Australia Scholarship to undertake research in the US. [ + ]
Spectral colour technology enables accurate colour imaging
In the near future, spectral imaging will provide new solutions for environmental monitoring and industrial quality control. [ + ]
Melanoma trial recruitment accelerating
Viralytics (ASX:VLA) has signed on 12 patients in the last three months for its phase II trial of oncolytic virus Cavatak in patients with late-stage melanoma. [ + ]
Alchemia appoints two new board members
Alchemia (ASX:ACL) has added an oncology expert and an international investment banking veteran to its board. [ + ]
New malaria drug could help combat resistance
Dr Aaron Nilsen and colleagues have discovered a new drug called ELQ-300 that can target multiple stages of the malaria parasite’s life cycle, including the liver stage, and could dramatically boost the prevention, treatment and transmission of disease. [ + ]
Chemical industry releases report on global megatrends
The Plastics and Chemicals Industries Association (PACIA) launched its foresighting report ‘Elements in Everything: Current profile and future trends for the Australian chemicals and plastics industries’ at Parliament House in Canberra this week. [ + ]
Genetics closer to understanding the elusive giant squid
Research suggests that there is just one single species of giant squid, capable of long-distance travel, rather than the 21 previously described species that were thought to exist. [ + ]
Patrys cancer antibody synergistic in myeloma
Animal trials of Patrys’s (ASX:PAB) anticancer antibody PAT-SM6 suggest the treatment is more effective when combined with other multiple myeloma treatments. [ + ]
Prima to get $4.7m grant for cancer vaccine
Prima BioMed (ASX:PRR) will receive a $4.7m grant from Saxony Development Bank and will use the funds to explore the use of CVac in more cancer types beyond ovarian. [ + ]
New treatment effective for chronic pain
A new device that stimulates the spinal cord provides relief for patients with difficult-to-treat chronic pain. [ + ]
iSonea unveils cloud asthma monitoring tool
iSonea (ASX:ISN) has used an Asthma Foundation conference to unveil AsthmaSense Cloud, a system for cloud storage and transfer of wheeze monitoring data. [ + ]
FDA rejects Pharmaxis’s NDA for Bronchitol
US regulator FDA has told Pharmaxis (ASX:PXS) that it will likely need to conduct a new phase III trial before Bronchitol can be approved as a cystic fibrosis treatment. [ + ]
